0001179022-18-000069.txt : 20180904 0001179022-18-000069.hdr.sgml : 20180904 20180904160855 ACCESSION NUMBER: 0001179022-18-000069 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180830 FILED AS OF DATE: 20180904 DATE AS OF CHANGE: 20180904 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rubin Marc CENTRAL INDEX KEY: 0001412377 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 181052468 MAIL ADDRESS: STREET 1: C/O TITAN PHARMACEUTICALS, INC. STREET 2: 400 OYSTER POINT BLVD., STE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-08-30 0001133416 GALECTIN THERAPEUTICS INC GALT 0001412377 Rubin Marc C/O GALECTIN THERAPEUTICS, INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE 240 NORCROSS GA 30071 1 0 0 0 Common Stock 2018-08-30 4 M 0 29000 0 A 84581 D Common Stock 2018-08-30 4 S 0 58100 6.0811 D 26481 D Stock option (right to buy) .89 2018-08-30 4 M 0 29000 0 D 2026-12-15 Common Stock 29000 22500 D The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018. The options vested 100% on December 14, 2017, the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.53. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. /s/ Jack W. Callicutt, by power of attorney 2018-09-04